help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First Published Online April 8, 2009
The Oncologist, Vol. 14, No. 4, 369-377, April 2009; doi:10.1634/theoncologist.2008-0119
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2008-0119v1
14/4/369    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allen-Auerbach, M.
Right arrow Articles by Weber, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allen-Auerbach, M.
Right arrow Articles by Weber, W. A.

Cancer Imaging

Measuring Response with FDG-PET: Methodological Aspects

Martin Allen-Auerbach, Wolfgang A. Weber

Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California, USA

Key Words. Fluorodeoxyglucose • Positron emission tomography • Chemotherapy • Radiotherapy • Response

Correspondence: Martin Allen-Auerbach, M.D., Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, Los Angeles, California 90095-6942, USA. Telephone: 310-794-7631; Fax: 310-206-4899; e-mail: mauerbach{at}mednet.ucla.edu

Received May 21, 2008; accepted for publication March 2, 2009; first published online in THE ONCOLOGIST Express on April 8, 2009.

Disclosures: Martin Allen-Auerbach: None; Wolfgang A. Weber: None.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers.

The use of fluorodeoxyglucose positron emission tomography (FDG-PET) for the evaluation of tumor response to chemotherapy and radiation therapy has been studied in a number of malignancies. By imaging tumor metabolism and therapy-related changes, FDG-PET has demonstrated advantages over anatomical imaging in the assessment of treatment response. More recent investigations have indicated that FDG-PET can predict tumor response early during the course of therapy, potentially allowing for early treatment adjustments. The aim of this review is to provide oncologists with a basic knowledge of the practical aspects of PET quantification for treatment.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.